Barclays PLC Raises Stake in Arcus Biosciences, Inc. (NYSE:RCUS)

Barclays PLC increased its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUSFree Report) by 183.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 470,776 shares of the company’s stock after acquiring an additional 304,683 shares during the period. Barclays PLC’s holdings in Arcus Biosciences were worth $8,451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its stake in shares of Arcus Biosciences by 8.0% in the first quarter. BlackRock Inc. now owns 10,139,020 shares of the company’s stock worth $184,936,000 after purchasing an additional 749,972 shares in the last quarter. State Street Corp raised its stake in shares of Arcus Biosciences by 55.1% during the 1st quarter. State Street Corp now owns 5,496,253 shares of the company’s stock worth $100,251,000 after purchasing an additional 1,951,970 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Arcus Biosciences by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,457,184 shares of the company’s stock valued at $116,600,000 after acquiring an additional 173,854 shares during the last quarter. Boxer Capital LLC increased its holdings in shares of Arcus Biosciences by 11.9% during the 2nd quarter. Boxer Capital LLC now owns 1,602,200 shares of the company’s stock valued at $32,541,000 after acquiring an additional 170,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Arcus Biosciences by 31.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,307,077 shares of the company’s stock valued at $23,839,000 after acquiring an additional 312,887 shares during the last quarter. 74.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RCUS has been the topic of a number of research analyst reports. Wedbush lowered their target price on Arcus Biosciences from $36.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, January 30th. Morgan Stanley reduced their price objective on Arcus Biosciences from $38.00 to $35.00 and set an “overweight” rating for the company in a research report on Monday, November 13th. Mizuho reduced their price objective on Arcus Biosciences from $51.00 to $42.00 and set a “buy” rating for the company in a research report on Tuesday, January 30th. Finally, Cantor Fitzgerald reduced their price objective on Arcus Biosciences from $46.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday, November 8th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Arcus Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $41.25.

Check Out Our Latest Stock Report on Arcus Biosciences

Insider Activity

In other news, major shareholder Gilead Sciences, Inc. bought 15,238,095 shares of the stock in a transaction dated Monday, January 29th. The stock was bought at an average cost of $21.00 per share, with a total value of $319,999,995.00. Following the purchase, the insider now owns 30,061,124 shares of the company’s stock, valued at $631,283,604. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In other Arcus Biosciences news, major shareholder Gilead Sciences, Inc. bought 15,238,095 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was purchased at an average cost of $21.00 per share, with a total value of $319,999,995.00. Following the completion of the purchase, the insider now owns 30,061,124 shares in the company, valued at $631,283,604. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Jennifer Jarrett sold 21,521 shares of the business’s stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $17.76, for a total value of $382,212.96. Following the completion of the transaction, the chief operating officer now directly owns 258,878 shares of the company’s stock, valued at $4,597,673.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,500 shares of company stock valued at $562,421. Company insiders own 13.80% of the company’s stock.

Arcus Biosciences Trading Down 3.3 %

Shares of RCUS opened at $14.82 on Thursday. The stock has a fifty day moving average price of $16.91 and a two-hundred day moving average price of $17.46. Arcus Biosciences, Inc. has a 52-week low of $12.95 and a 52-week high of $25.47.

Arcus Biosciences (NYSE:RCUSGet Free Report) last issued its quarterly earnings data on Tuesday, November 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.18. Arcus Biosciences had a negative return on equity of 50.02% and a negative net margin of 244.17%. The firm had revenue of $32.00 million during the quarter, compared to the consensus estimate of $27.57 million. During the same quarter in the previous year, the company posted ($0.90) EPS. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. Analysts expect that Arcus Biosciences, Inc. will post -4.09 earnings per share for the current year.

Arcus Biosciences Company Profile

(Free Report)

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.

Recommended Stories

Want to see what other hedge funds are holding RCUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcus Biosciences, Inc. (NYSE:RCUSFree Report).

Institutional Ownership by Quarter for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.